CeriBell (NASDAQ:CBLL) CEO Xingjuan Chao Sells 2,199 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 2,199 shares of CeriBell stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $25.00, for a total transaction of $54,975.00. Following the transaction, the chief executive officer directly owned 819,214 shares in the company, valued at $20,480,350. This represents a 0.27% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Xingjuan Chao also recently made the following trade(s):

• On Wednesday, August 19th, Xingjuan Chao sold 31,415 shares of CeriBell stock. The shares were sold at an average price of $25.03, for a total value of $786,317.45.
• On Tuesday, July 7th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $19.90, for a total value of $776,100.00.
• On Monday, June 8th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $18.33, for a total transaction of $714,870.00.

CeriBell Price Performance

Shares of NASDAQ:CBLL opened at $24.31 on Friday. The firm has a fifty day moving average price of $19.43 and a 200 day moving average price of $19.19. CeriBell, Inc. has a fifty-two week low of $10.85 and a fifty-two week high of $25.33. The firm has a market cap of $933.02 million, a price-to-earnings ratio of -13.81 and a beta of 0.81. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.79 and a current ratio of 9.18.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The firm had revenue of $28.10 million during the quarter, compared to analysts’ expectations of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. As a group, sell-side analysts expect that CeriBell, Inc. will post -1.96 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Canaccord Genuity Group lifted their price target on shares of CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. BTIG Research upped their target price on CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday. Barclays raised shares of CeriBell to a “neutral” rating in a research report on Tuesday. Finally, Weiss Ratings raised CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.40.

Institutional Investors Weigh In On CeriBell

A number of large investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in CeriBell in the second quarter valued at $37,657,000. Bank of New York Mellon Corp raised its position in CeriBell by 1,945.9% during the fourth quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock valued at $26,797,000 after acquiring an additional 1,162,200 shares in the last quarter. KCM Capital Inc acquired a new stake in shares of CeriBell during the 4th quarter worth approximately $21,930,000. TimesSquare Capital Management LLC acquired a new stake in CeriBell during the second quarter valued at $15,182,000. Finally, Royce & Associates LP purchased a new position in CeriBell in the fourth quarter valued at $11,695,000.

Key CeriBell News

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: BTIG raised its price target to $30 and reiterated a Buy rating, signaling confidence in CeriBell’s growth outlook. Canaccord Genuity also raised its target to $26 and maintained a Buy rating. CeriBell Stock Price Expected to Rise, BTIG Research Analyst Says
• Positive Sentiment: Institutional ownership activity was generally constructive, with several firms adding to or initiating small positions in CBLL. Barclays also upgraded the shares to Neutral, while the broader analyst consensus remains “Moderate Buy.”
• Neutral Sentiment: CeriBell’s latest quarter showed mixed results: revenue of $28.10 million exceeded estimates of $27.28 million, but adjusted EPS of negative $0.51 missed the consensus loss estimate of negative $0.47. The company remains unprofitable, with analysts expecting a full-year loss.
• Negative Sentiment: CEO Xingjuan Chao sold 31,415 shares for approximately $786,000 at an average price of $25.03, reducing her ownership by 3.83%. She also sold 2,199 shares the prior day and has made additional sales in recent months. Xingjuan Chao Sells Shares of CeriBell
• Negative Sentiment: CFO Scott Blumberg sold 33,512 shares worth approximately $839,000 and an additional 990 shares, reducing his direct holdings by about 18.45% overall. Multiple senior-executive sales near the stock’s recent highs may reinforce profit-taking concerns and help explain the stock’s decline.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.